Hemoglobinopathies Industry Overview The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market. Hemoglobinopathies Market Segmentation Grand View Research has segmented the global hemoglobinopathies market on the basis of type, diagnosis, therapy, and region: Based on the Type Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.
Based on the Diagnosis Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.
Based on the Therapy Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.
Hemoglobinopathies Regional Outlook
Key Companies Profile & Market Share Insights Market players are taking up various initiatives, such as mergers & acquisitions, partnerships, collaborations, and extensive R&D, in order to gain a greater share in the market. Some prominent players in the global hemoglobinopathies market include
Order a free sample PDF of the Hemoglobinopathies Market Intelligence Study, published by Grand View Research.
0 Comments
Leave a Reply. |
Archives
December 2023
Categories |